<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7605074</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6087</journal-id>
<journal-id journal-id-type="nlm-ta">Neuroscience</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuroscience</journal-id>
<journal-title-group>
<journal-title>Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0306-4522</issn>
<issn pub-type="epub">1873-7544</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27646291</article-id>
<article-id pub-id-type="pmc">5458638</article-id>
<article-id pub-id-type="doi">10.1016/j.neuroscience.2016.09.012</article-id>
<article-id pub-id-type="manuscript">NIHMS820527</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rodent Models of Obsessive Compulsive Disorder: Evaluating Validity to Interpret Emerging Neurobiology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zike</surname>
<given-names>Isaac</given-names>
</name>
<!--<email>isaac.zike@vanderbilt.edu</email>-->
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Tim</given-names>
</name>
<!--<email>tim.xu@jhmi.edu</email>-->
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hong</surname>
<given-names>Natalie</given-names>
</name>
<!--<email>nah2026@med.cornell.edu</email>-->
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Veenstra-VanderWeele</surname>
<given-names>Jeremy</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA</aff>
<aff id="A2"><label>b</label>Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA</aff>
<aff id="A3"><label>c</label>Center for Autism and the Developing Brain, New York Presbyterian Hospital and Cornell University Medical College, White Plains, NY, 10605, USA</aff>
<aff id="A4"><label>d</label>Sackler Institute for Developmental Psychobiology and Department of Psychiatry, Columbia University, New York, NY, 10032, USA</aff>
<aff id="A5"><label>e</label>New York State Psychiatric Institute, New York, NY, 10032, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding Author: Jeremy Veenstra-VanderWeele, 1051 Riverside Drive, Mail Unit 78, New York NY 10032, Tel: 646-774-5251, <email>veenstr@nyspi.columbia.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p><bold>Biomedical conflicts of interest</bold>: Dr. Veenstra-VanderWeele has consulted with Roche Pharmaceuticals, Novartis, and SynapDx and has had research funding from Roche Pharmaceuticals, Novartis, SynapDx, Seaside Therapeutics, Forest, and Sunovion. He receives an honorarium for editorial work from Springer and John Wiley and Sons.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>14</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>14</day>
<month>3</month>
<year>2018</year>
</pub-date>
<volume>345</volume>
<fpage>256</fpage>
<lpage>273</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuroscience.2016.09.012-->
<abstract>
<p id="P1">Obsessive Compulsive Disorder (OCD) is a common neuropsychiatric disorder with unknown molecular underpinnings. Identification of genetic and non-genetic risk factors has largely been elusive, primarily because of a lack of power. In contrast, neuroimaging has consistently implicated the cortico-striatal-thalamo-cortical (CSTC) circuits in OCD. Pharmacological treatment studies also show specificity, with consistent response of OCD symptoms to chronic treatment with serotonin reuptake inhibitors; although most patients are left with residual impairment. In theory, animal models could provide a bridge from the neuroimaging and pharmacology data to an understanding of pathophysiology at the cellular and molecular level. Several mouse models have been proposed using genetic, immunological, pharmacological, and optogenetic tools. These experimental model systems allow testing of hypotheses about the origins of compulsive behavior. Several models have generated behavior that appears compulsive-like, particularly excessive grooming, and some have demonstrated response to chronic serotonin reuptake inhibitors, establishing both face validity and predictive validity. Construct validity is more difficult to establish in the context of a limited understanding of OCD risk factors. Our current models may help us to dissect the circuits and molecular pathways that can elicit OCD-relevant behavior in rodents. We can hope that this growing understanding, coupled with developing technology, will prepare us when robust OCD risk factors are better understood.</p>
</abstract>
<kwd-group>
<kwd>Repetitive behavior</kwd>
<kwd>basal ganglia</kwd>
<kwd>striatum</kwd>
<kwd>optogenetic</kwd>
<kwd>autoimmune</kwd>
<kwd>autism</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>